Review Article
The G Allele of CaSR R990G Polymorphism Increases Susceptibility to Urolithiasis and Hypercalciuria: Evidences from a Comprehensive Meta-Analysis
Table 3
Summary OR and 95% CI of the CaSR polymorphisms and urolithiasis risk.
(a) A986S |
| | | AS versus AA | | SS versus AA | | SS versus AA/AS | | | AS/SS versus AA | |
| Total | 9 | 0.97 (0.79–1.19) | 0.261 | 1.04 (0.48–2.25) | 0.060 | 1.08 (0.53–2.19) | 0.099 | 10 | 0.94 (0.71–1.25) | 0.031 | Ethnicity | | | | | | | | | | | Asian | 4 | 1.64 (1.04–2.59) | 0.549 | 4.18 (0.84–20.86) | 0.770 | 3.97 (0.80–19.76) | 0.782 | 4 | 1.78 (1.13–2.80) | 0.591 | Caucasian | 5 | 0.85 (0.67–1.07) | 0.778 | 0.74 (0.31–1.80) | 0.029 | 0.81 (0.35–1.85) | 0.047 | 6 | 0.78 (0.62–0.99) | 0.257 | Subjects | | | | | | | | | | | PHPT and healthy | 3 | 0.98 (0.48–1.41) | 0.918 | 1.35 (0.60–3.02) | 0.412 | 1.35 (0.61–3.00) | 0.421 | 3 | 1.03 (0.73–1.45) | 0.773 | PHPT patients | 3 | 0.70 (0.44–1.10) | 0.690 | 0.38 (0.10–1.42) | 0.221 | 0.44 (0.12–1.44) | 0.248 | 3 | 0.62 (0.40–0.96) | 0.351 | Healthy population | 3 | 1.10 (0.82–1.47) | 0.038 | 1.95 (0.91–4.18) | 0.667 | 2.07 (0.95–4.52) | 0.512 | 4 | 1.13 (0.65–1.96) | 0.009 | SOC | | | | | | | | | | | PB | 5 | 1.07 (0.84–1.36) | 0.156 | 1.72 (0.97–3.05) | 0.641 | 1.74 (0.99–3.06) | 0.664 | 6 | 1.10 (0.77–1.57) | 0.035 | HB | 4 | 0.74 (0.50–1.10) | 0.809 | 0.40 (0.16–1.02) | 0.330 | 0.44 (0.19–1.00) | 0.376 | 4 | 0.67 (0.46–0.96) | 0.442 |
|
|
(b) R990G |
| | | RG versus RR | | GG versus RR | | GG versus RR/RG | | | RG/GG versus RR | |
| Total | 6 | 1.45 (0.90–2.34) | 0.029 | 1.90 (0.49–7.30) | 0.000 | 1.84 (0.53–6.43) | 0.000 | 9 | 2.10 (1.23–3.58) | 0.001 | Ethnicity | | | | | | | | | | | Asian | 3 | 1.27 (0.54–2.96) | 0.059 | 0.63 (0.26–1.51) | 0.213 | 0.65 (0.32–1.33) | 0.246 | 3 | 1.26 (0.47–3.40) | 0.017 | Caucasian | 3 | 1.74 (0.88–3.42) | 0.063 | 7.01 (2.85–17.27) | 0.745 | 6.73 (2.74–16.53) | 0.717 | 6 | 2.71 (1.50–4.91) | 0.044 | Subjects | | | | | | | | | | | PHPT and healthy | 2 | 1.11 (0.65–1.90) | 0.223 | 1.07 (0.07–15.53) | 0.105 | 1.07 (0.09–12.75) | 0.123 | 3 | 1.45 (0.61–3.41) | 0.014 | PHPT patients | 2 | 2.40 (0.28–20.65) | 0.009 | 0.76 (0.30–1.96) | 0.575 | 0.79 (0.35–1.81) | 0.646 | 3 | 3.61 (0.55–23.84) | 0.004 | Healthy population | 2 | 2.28 (0.50–10.45) | 0.051 | 7.57 (3.00–19.11) | 0.877 | 7.27 (2.89–18.31) | 0.851 | 3 | 3.36 (1.00–11.28) | 0.064 | SOC | | | | | | | | | | | PB | 4 | 1.31 (0.83–2.08) | 0.123 | 2.87 (0.37–22.43) | 0.000 | 2.83 (0.39–20.63) | 0.000 | 5 | 1.64 (0.90–3.01) | 0.013 | HB | 2 | 2.40 (0.28–20.65) | 0.009 | 0.76 (0.30–1.96) | 0.575 | 0.79 (0.35–1.81) | 0.646 | 4 | 3.40 (0.97–11.85) | 0.004 |
|
|
(c) Q1011E |
| | | QE versus QQ | | EE versus QQ | | EE versus QQ/QE | | | QE/EE versus QQ | |
| Total | 4 | 1.59 (0.91–2.81) | 0.201 | 2.20 (0.40–12.07) | 0.863 | 2.14 (0.39–11.75) | 0.859 | 4 | 1.59 (0.91–2.81) | 0.201 |
|
|
Number of studies
b value of test for heterogeneity SOC: Source of controls, HB: hospital-based control group, and PB: population-based control group.
|